Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.50 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717534 | 0.86 | MAPT (0.59) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL30003409 | 0.86 | KCNJ1 (0.61) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL3358360 | 0.86 | KCNJ1 (0.61) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL354153 | 0.82 | KDM4E (0.66) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL14376686 | 0.82 | MAPT (0.58) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL26971044 | 0.82 | MAPT (0.65) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL22335796 | 0.80 | MAPT (0.51) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL14239872 | 0.78 | HCAR2 (0.45) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL5668014 | 0.77 | MAPT (0.50) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL1612695 | 0.77 | MEN1 (0.51) | MAPTLMNAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | CURIS ROYALTY LLC | 2006-03-23 | — | — | US | disclosed |
| US-20050222410-A1 | Inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| EP-1501508-A1 | INHIBITORS OF HISTONE DEACETYLASE | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092686-A1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | MAPT 3557/4885LMNA 1672/4885KDM4E 1204/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | MAPT 2157/4885LMNA 2153/4885KDM4E 1198/4885 |
| US-20050222410-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | MAPT 3430/4885LMNA 596/4885KDM4E 86/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | MAPT 2157/4885LMNA 2153/4885KDM4E 1198/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3822/4885LMNA 3716/4885KDM4E 411/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPT 3696/4885LMNA 3718/4885KDM4E 382/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | MAPT 3557/4885LMNA 1672/4885KDM4E 1204/4885 |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | MAPT 2133/4885LMNA 599/4885KDM4E 3251/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | MAPT 2157/4885LMNA 2153/4885KDM4E 1198/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAPT 3314/4885LMNA 3309/4885KDM4E 2322/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | MAPT 2865/4885LMNA 3454/4885KDM4E 4059/4885 |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | SHH, GLI1, SMO | MAPT 3822/4885LMNA 3716/4885KDM4E 411/4885 |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | MAPT 4540/4885LMNA 493/4885KDM4E 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.